Market Research Report
Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast - 2030
|Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast - 2030|
DelveInsight Business Research LLP
Content info: 166 Pages
Delivery time: 2-10 business days
DelveInsight's 'Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast - 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Obstructive Sleep Apnea in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Obstructive Sleep Apnea market report provides analysis regarding current treatment practices, emerging drug-like AD036 and AD128 (Apnimed) and BAY2586116 (Bayer's) potential therapies, market share of the individual therapies, historical, current, and forecasted Obstructive Sleep Apnea market size from 2017 to 2030 segmented by seven major markets.
The report also covers current Obstructive Sleep Apnea treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the market's underlying potential.
Study Period: 2017-2030
Obstructive Sleep Apnea (OSA) is a sleep-related breathing disorder that involves a decrease or complete halt in airflow despite an ongoing effort to breathe. It occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to collapse and block the upper airway. Obstructive Sleep Apnea (OSA) may manifest in several ways, from subtle intrusion into daily life to profound sleepiness, snoring, witnessed Apneas, and other symptoms.
This chapter covers the details of conventional and current medical therapies available in the Obstructive Sleep Apnea market to treat the condition. It also provides the country-wise Obstructive Sleep Apnea treatment guidelines across the United States, Europe, and Japan.
DelveInsight's Obstructive Sleep Apnea market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Obstructive Sleep Apnea treatment algorithms and treatment guidelines in the US, Europe, and Japan.
The current treatment landscape of OSA mainly comprises options including continuous positive airway pressure (CPAP), oral appliances therapy, surgery, and lifestyle changes such as weight loss or body positioning during sleep. Among all these, CPAP is the standard gold treatment for OSA and occupies the largest market share (devices). However, PAP remains the most preferred mode of treating OSA, as per expert opinions, despite this, about 10% of the patients experience excessive daytime sleepiness. To combat this, these patients are further treated with wakefulness promoters [Modafinil, Armodafinil, and solriamfetol].
The Obstructive Sleep Apnea epidemiology chapters provide insights about historical and current Obstructive Sleep Apnea patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Obstructive Sleep Apnea epidemiology is segmented by Total diagnosed prevalent cases of OSA, Gender-specific cases of Obstructive Sleep Apnea, Age-specific cases of Obstructive Sleep Apnea, Severity-specific cases of OSA. The report includes a thorough analysis of all segmentations.
According to DelveInsight's estimate, the total diagnosed prevalent cases of Obstructive Sleep Apnea in 7MM countries were found to be 283,026 cases in 2017. Among all the seven major markets, the United States accounts for the highest number of Obstructive Sleep Apnea cases.
In the US, the diagnosed prevalence of Obstructive Sleep Apnea was 169,439 cases in 2017, whereas Japan had 33,406 cases of Obstructive Sleep Apnea in 2017.
The drug chapter segment of the Obstructive Sleep Apnea report encloses a detailed analysis of the Obstructive Sleep Apnea pipeline drug. It also helps understand the Obstructive Sleep Apnea clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.
To date, few drugs have been developed which address the underlying cause of OSA, and since the entire landscape is devoid of any effective pharmaceutical treatment option, any significant development in this direction is expected to create a tectonic impact on the existing market scenario during our forecast period.
The Obstructive Sleep Apnea market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Obstructive Sleep Apnea market size, with USD 165.3 million in 2017. Japan's market size of Obstructive Sleep Apnea was USD 15.1 million in the same year.
This section focuses on the rate of uptake of the potential drugs in the Obstructive Sleep Apnea market that are expected to get launched in the market during the study period 2017-2030. The analysis covers Obstructive Sleep Apnea market uptake by drugs, patient uptake by therapies, and sale of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of the Obstructive Sleep Apnea market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Obstructive Sleep Apnea key players involved in developing targeted therapeutics.
The report covers the detailed information of Obstructive Sleep Apnea collaborations, acquisition, and merger, licensing patent details, and other information for Obstructive Sleep Apnea emerging therapies.
Approaching reimbursement, proactively, can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in the Obstructive Sleep Apnea domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Obstructive Sleep Apnea Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
The United States accounted for the largest Obstructive Sleep Apnea market size.
DelveInsight estimates an increase in Obstructive Sleep Apnea Market Size during the study period, 2017-2030
Upcoming pipeline, big data, and personalized therapy.
Economic cost, the efficacy of current treatment, and future competition are likely to block the market growth.
Many companies are working robustly in providing effective treatment to the individuals suffering from OSA like, Apnimed, Bayer, Idorsia, and others.
Key Players- Apnimed, Bayer, etc.
Diagnosed prevalent cases of OSA, Gender-specific cases of Obstructive Sleep Apnea, Age-specific cases of OSA, and Severity-specific cases of Obstructive Sleep Apnea.